JP2016517435A - メロペネム誘導体及びその使用 - Google Patents

メロペネム誘導体及びその使用 Download PDF

Info

Publication number
JP2016517435A
JP2016517435A JP2016502851A JP2016502851A JP2016517435A JP 2016517435 A JP2016517435 A JP 2016517435A JP 2016502851 A JP2016502851 A JP 2016502851A JP 2016502851 A JP2016502851 A JP 2016502851A JP 2016517435 A JP2016517435 A JP 2016517435A
Authority
JP
Japan
Prior art keywords
compound
certain embodiments
pharmaceutical composition
kda
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016502851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016517435A5 (ja
Inventor
ウィンストン ザパンタ オング
ウィンストン ザパンタ オング
パウェル ヴォイチェフ ノーワーク
パウェル ヴォイチェフ ノーワーク
ジンスー キム
ジンスー キム
エリザベス エム エンロウ
エリザベス エム エンロウ
ジェイムズ ブーラッサ
ジェイムズ ブーラッサ
イェン ク
イェン ク
アレクセイ ポポフ
アレクセイ ポポフ
チェン　ホンミン
ホンミン チェン
Original Assignee
カラ ファーマシューティカルズ インコーポレイテッド
カラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カラ ファーマシューティカルズ インコーポレイテッド, カラ ファーマシューティカルズ インコーポレイテッド filed Critical カラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2016517435A publication Critical patent/JP2016517435A/ja
Publication of JP2016517435A5 publication Critical patent/JP2016517435A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016502851A 2013-03-15 2014-03-14 メロペネム誘導体及びその使用 Ceased JP2016517435A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789335P 2013-03-15 2013-03-15
US61/789,335 2013-03-15
PCT/US2014/028627 WO2014144285A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019023946A Division JP6738918B2 (ja) 2013-03-15 2019-02-13 メロペネム誘導体及びその製造法

Publications (2)

Publication Number Publication Date
JP2016517435A true JP2016517435A (ja) 2016-06-16
JP2016517435A5 JP2016517435A5 (ja) 2017-03-30

Family

ID=51537664

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502851A Ceased JP2016517435A (ja) 2013-03-15 2014-03-14 メロペネム誘導体及びその使用
JP2019023946A Expired - Fee Related JP6738918B2 (ja) 2013-03-15 2019-02-13 メロペネム誘導体及びその製造法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019023946A Expired - Fee Related JP6738918B2 (ja) 2013-03-15 2019-02-13 メロペネム誘導体及びその製造法

Country Status (8)

Country Link
US (4) US9725451B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968274B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016517435A (cg-RX-API-DMAC7.html)
AU (2) AU2014227737B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023621A8 (cg-RX-API-DMAC7.html)
CA (1) CA2906689A1 (cg-RX-API-DMAC7.html)
HK (1) HK1219233A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014144285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362239B (zh) * 2020-03-20 2021-07-06 辽宁瑞鸥新材料科技有限公司 一种用于铝硅系合金半固态制浆的Cs2HPO4气溶胶及其使用方法
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2022231998A1 (en) * 2021-04-27 2022-11-03 Theaprin Pharmaceuticals, Inc. Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023359A (ja) * 1983-06-23 1985-02-05 メルク・エンド・カムパニ−・インコ−ポレ−テツド 薬物中の１級及び２級アミン官能基のための生物可逆性前駆薬部分としての（アシロキシアルコキシ）カルボニル誘導体
JPS60209589A (ja) * 1984-04-02 1985-10-22 アメリカン・サイアナミド・カンパニ− セフアロスポリン誘導体のエステル
JPS6247874B2 (cg-RX-API-DMAC7.html) * 1983-01-28 1987-10-09 Burisutoru Maiyaazu Kenkyusho Kk
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
WO2002094829A1 (en) * 2001-05-21 2002-11-28 Kyoto Pharmaceutical Industries, Ltd. Carbapenem compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6247874A (ja) 1985-08-27 1987-03-02 Sankyo Seiki Mfg Co Ltd プログラム動作装置の初期化方法
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
WO1997049387A1 (en) 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
KR100589030B1 (ko) 1998-05-01 2006-06-13 교토 야쿠힝 고교 가부시키가이샤 카르바페넴 유도체, 그 사용 방법 및 그 중간체 화합물
JP2000344772A (ja) 1998-05-01 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、その用途およびその中間体化合物
JP2000344774A (ja) * 1999-06-03 2000-12-12 Meiji Seika Kaisha Ltd カルバペネム類の製造法
US20050065141A1 (en) * 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP2085084A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EA201370107A1 (ru) 2010-11-11 2013-11-29 Редкс Фарма Лимитед Производные лекарственных средств
NZ722096A (en) * 2011-12-15 2016-11-25 Alkermes Pharma Ireland Ltd Prodrugs of secondary amine compounds
NZ728721A (en) 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6247874B2 (cg-RX-API-DMAC7.html) * 1983-01-28 1987-10-09 Burisutoru Maiyaazu Kenkyusho Kk
JPS6023359A (ja) * 1983-06-23 1985-02-05 メルク・エンド・カムパニ−・インコ−ポレ−テツド 薬物中の１級及び２級アミン官能基のための生物可逆性前駆薬部分としての（アシロキシアルコキシ）カルボニル誘導体
JPS60209589A (ja) * 1984-04-02 1985-10-22 アメリカン・サイアナミド・カンパニ− セフアロスポリン誘導体のエステル
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
WO2002094829A1 (en) * 2001-05-21 2002-11-28 Kyoto Pharmaceutical Industries, Ltd. Carbapenem compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NAJAFABADI, A. R. ET AL.: "The effect of micronization method on characterization and deposition profiles of different dry powd", JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol. 16(5), JPN6018003030, 2006, pages 363 - 368, ISSN: 0003730133 *
TANAKA, SHUNKICHI ET AL.: "Novel prodrugs of meropenem with two lipophilic pro-moieties: synthesis and pharmacokinetics", JOURNAL OF ANTIBIOTICS, vol. 64(3), JPN6018003028, 2011, pages 233 - 242, ISSN: 0003730132 *

Also Published As

Publication number Publication date
US9725451B2 (en) 2017-08-08
EP2968274B1 (en) 2019-10-16
BR112015023621A8 (pt) 2018-01-23
JP6738918B2 (ja) 2020-08-12
BR112015023621A2 (pt) 2017-07-18
US20210332048A1 (en) 2021-10-28
CA2906689A1 (en) 2014-09-18
JP2019089829A (ja) 2019-06-13
US11091487B2 (en) 2021-08-17
US10392388B2 (en) 2019-08-27
AU2018203005A1 (en) 2018-05-17
US20170349590A1 (en) 2017-12-07
EP2968274A1 (en) 2016-01-20
AU2014227737B2 (en) 2018-05-17
WO2014144285A1 (en) 2014-09-18
EP2968274A4 (en) 2016-08-24
US20160039823A1 (en) 2016-02-11
HK1219233A1 (zh) 2017-03-31
AU2014227737A1 (en) 2015-10-08
US20200010470A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
US20210332048A1 (en) Meropenem derivatives and uses thereof
JP6830943B2 (ja) 治療用化合物および医薬組成物
US10398703B2 (en) Therapeutic compounds and uses thereof
JP6469661B2 (ja) 尿素誘導体及びその使用
US20210380588A1 (en) Novel Compounds and Uses Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151218

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20151218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20151218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190115

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20190528